Peripheral Arterial Occlusive DiseasePhase 2HEALINGNCT07352800
Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia
A Phase 2 study testing APAC - dose level 0.50 mg/kg,, Unfractionated heparin (UFH) and APAC dose level 1: 0.25 mg/kg, in people with Peripheral Arterial Occlusive Disease and Chronic Limb-Threatening Ischemia, run by Aplagon Oy at 3 sites in Finland.
Trial summary
The goal of this study is to learn if a new medicine (called antiplatelet and anticoagulant [APAC]) can help the body to prevent blood clots and whether APAC is safe and well tolerated in patients with blocked or narrowed arteries in their legs (peripheral arterial occlusive disease [PAOD]), and in patients with… Read more about this study
- Who is it for?
- Ages Up to 85 years
- Conditions the study is for
- Peripheral Arterial Occlusive Disease, Chronic Limb-Threatening Ischemia
- What is being tested?
- APAC - dose level 0.50 mg/kg,, Unfractionated heparin (UFH) and APAC dose level 1: 0.25 mg/kg,
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 42 participants
- Where
- 3 sitesFinland
- Study dates
- 29 Jan 2026to 30 Jun 2027
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 85 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Males aged 45-85 years and postmenopausal females (i.e., no menstrual periods for 12 months without an alternative medical cause) up to 85 years.
- Diagnosed with a. PAOD classification Fontaine stage III or IV , b. the total length of the treatment-targeted arterial segment ≥ 5 cm below the knee lesion(s) based on contrast-enhanced computed tomography angiography (CTA)/magnetic resonance angiography (MRA)/digital subtraction angiography (DSA) (Part B1 and B2), c. superficial forefoot wounds without overt infection and bone invasion (WIfI 0-1 and 2 limited to digits and WIfI infection 0-1) allowed, d. undergoing endovascular intervention. (In Part A1, if prescheduled endovascular intervention would take place before the Day 8 study visit, patient is not to be enrolled.)
- CTA/MRA/DSA with contrast agent performed within 3 months prior to study enrolment as part of diagnostics of PAOD, with results available in the patient's medical records.
- Patients should be treated with antithrombotic medication either acetylsalicylic acid (up to 100 mg once a day [QD]) or clopidogrel (up to 75 mg QD) for at least the preceding five days before the first APAC administration.
- Adequate lipid lowering therapy, as evaluated by the investigator.
- Capability and willingness to provide valid, voluntary written informed consent for the study.
Show all 17Show fewer
- Males must be willing to use a condom and their female partners of childbearing potential (i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile [hysterectomy, bilateral salpingectomy and bilateral oophorectomy]) must be willing to use highly effective contraception while on study treatment. Highly effective methods include: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal); progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable); intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomized partner; and sexual abstinence.
- Males must refrain from sperm donation while on study treatment.
- Males aged 45-85 years and postmenopausal females (i.e., no menstrual periods for 12 months without an alternative medical cause) up to 85 years.
- Diagnosed with a. PAOD classification Fontaine stage IIa and IIb, b. not prescheduled for endovascular revascularization within 90 days of first APAC administration.
- Moderate to severe arterial disease, ABI < 0.7.
- Patients should be capable of performing evaluable treadmill exercise test.
- Patients should be treated with antithrombotic medication either acetylsalicylic acid (up to 100 mg QD) or clopidogrel (up to 75 mg QD) for at least the preceding five days before the first APAC administration.
- Adequate lipid lowering therapy, as evaluated by the investigator.
- Capability and willingness to provide valid, voluntary written informed consent for the study.
- Males must be willing to use a condom and their female partners of childbearing potential (i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile [hysterectomy, bilateral salpingectomy and bilateral oophorectomy]) must be willing to use highly effective contraception while on study treatment. Highly effective methods include: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal); progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable); IUD; IUS; bilateral tubal occlusion; vasectomized partner; and sexual abstinence.
- Males must refrain from sperm donation while on study treatment.
Who cannot join
- Any ischemic lesions of the heel and midfoot and lesions (wounds or gangrene) invading bones, joints, or tendons at metatarsophalangeal joints or more proximal sites.
- Acute limb-threatening ischemia (e.g., thromboembolic disease).
- Medical history of, or an existing aneurysm.
- Endovascular revascularization intervention is done from the contralateral side using cross-over access (Part B1 and B2).
- Medical history of, or condition known to be associated with impaired hemostasis, i.e., increased intracranial bleeding risk e.g., previous history of intracranial hemorrhage, subarachnoidal bleeding, hemorrhagic stroke, thrombotic or thromboembolic stroke, gastrointestinal bleeding within 6 months of enrolment, or retroperitoneal bleeding any time, or any inherited or acquired bleeding disorder, i.e., von Willebrand disease or hemophilia or other relevant diagnosis causing impaired hemostasis.
- Current use of therapeutic dose of anticoagulation (warfarin, apixaban, rivaroxaban, dabigatran, edoxaban, fondaparinux, or any heparin derivative) for any medical reason. (Use of dual pathway inhibition [= acetylsalicylic acid 100 mg + rivaroxabahn 2.5 mg x 2] is not a contraindication, but will be temporarily halted for the day of intervention and day of repeating dosing)
Show all 32Show fewer
- Patients treated with combined antiplatelet agents: aspirin + P2Y12 antagonist (clopidogrel, ticagrelor, prasugrel).
- Diagnosis of autoimmune diabetes mellitus (Type 1 diabetes, or latent autoimmune diabetes in adults [LADA]) vasculitis, rheumatoid arthritis, inflammatory bowel diseases, or other general autoimmune diseases.
- Body mass index > 35 kg/m^2.
- Patients with clinically significant acute infection, as judged by the investigator.
- Use of non-steroidal anti-inflammatory medications within 2 weeks prior to the first dose of APAC or during the treatment period. If medication for pain is required, paracetamol or tramadol (e.g. an opioid patch) may be used.
- Use of selective serotonin reuptake inhibitor (SSRI) medication within 2 weeks prior to the first dose of APAC or during the treatment period.
- Peroral use of glycosaminoglycans or omega 3 or related products within 28 days before IMP treatment.
- Major surgery, major trauma or any endovascular intervention within the past 90 days or organ biopsy prior to the screening visit or scheduled for such an intervention during the study.
- Uncontrolled arterial hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg).
- Blood hemoglobin concentration <120 g/L or > 170 g/L (men) and <110 g/L or >160 g/L (women) at screening.
- Blood platelet count <150 x 10^9/L or > 450 x10^9/L and/or leukocyte count in the lower reference range or not above >12 x 10^9/L.
- Clinically significantly prolonged plasma PT (> 1.2-fold) or a value of less than 50% (when normal reference range is 70-130%).
- APTT above the upper limit of the reference range.
- Patients with a medical history of heparin-induced thrombocytopenia.
- Patients with known significant liver disease, incl. an alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) level > 2.5 x the upper limit of normal (ULN) at screening.
- A diagnosis of severe chronic kidney disease, defined as having an eGFR category 4 or 5 (eGFR < 30 mL/min/1.73 m2 as per calculation of Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) or albuminuria stage A3 (uACR >300 mg/g).
- Patients with an active malignancy, or who have received treatment for any malignancy including bone marrow transplantation within 5 years before the screening visit, except for localized basal cell or squamous cell skin cancer that has been cured at least 90 days before screening.
- Previous treatment with APAC.
- Patients with known allergy or hypersensitivity to heparin, or heparin products, APAC, and/or antiplatelet agents (e.g., aspirin or clopidogrel), and protamine sulphate, the reversal agent for APAC.
- Participation in an investigational drug or device study within 90 days prior to screening.
- Patients who have ever received treatment with a gene therapy.
- Patients with known antiphospholipid antibody syndrome or other known significant thrombophilia (homozygosity for FV Leiden or FIIG20210A mutation, or phospholipid antibody syndrome, deficiency of antithrombin, protein C or protein S or combined thrombophilia).
- Any concomitant disease or condition or treatment that could interfere with, or the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the patient in this study as judged by the investigator.
- Patients with severe comorbidities and limited life expectancy as judged by the investigator.
- Patients unable or unwilling to comply with the protocol or to cooperate fully with the investigator or site personnel.
- Patients with current and/or history of drug abuse (defined as illicit drug use) or alcohol abuse (defined as daily consumption of more than 23-24 and 12-16 alcoholic drinks per week in males and females, respectively).
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Finland3 sites, 3 recruiting
- Recruiting
Helsinki University Hospital
Helsinki, 00290
Maarit Venermo, +358 9 4711, maarit.venermo@hus.fi
- Recruiting
Tampere University Hospital
Tampere
Eva Saarinen, +358 3 311 611, eva.saarinen@pirha.fi
- Recruiting
Turku University Hospital
Turku
Harri Hakovirta, +358 2 313 0000, harri.hakovirta@varha.fi
About this study
Official title: A Phase 2a Open-label Study to Assess the Safety, Tolerability, and Dosing Regimen of Antithrombotic Heparin Proteoglycan Mimetic APAC in Patients With Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia Undergoing Endovascular Revascularization
The goal of this study is to learn if a new medicine (called antiplatelet and anticoagulant [APAC]) can help the body to prevent blood clots and whether APAC is safe and well tolerated in patients with blocked or narrowed arteries in their legs (peripheral arterial occlusive disease [PAOD]), and in patients with severely restricted poor blood flow to the legs that threatens limb health (chronic limb-threatening ischemia [CTLI]). The study also aims to find the best dose of the medicine. The study consists of two parts: Part A will include patients with PAOD and CTLI, Part B will only include patients with CTLI who are having a procedure to restore blood flow in their legs. Both parts will be subdivided into two subgroups (A1 and A2, B1 and B2) which will test different APAC doses and compare single dosing to weekly dosing for 4 weeks. APAC is injected into the blood. The possible treatment response will be compared either to a placebo (a look-alike substance that contains no drug), or to the current standard treatment. Patients will participate in the study for up to 90 or 180 days. During this time, patients will be regularly examined and asked to answer questions concerning their quality of life.
Read the detailed description
Peripheral arterial occlusive disease is a group of vascular disorders characterized by narrowing and occlusion of peripheral arteries, often resulting in gradual reduction of the blood supply to the limbs. The main pathogenic mechanism of PAOD stems from atherosclerosis, thrombo-inflammation and thrombosis (atherothrombosis). Patients with PAOD are at increased risk of major adverse limb events (MALE, defined as above ankle amputation of the index limb or major reintervention) and major adverse cardiovascular events (MACE). The most severe form of PAOD, CTLI, is characterized by severely decreased blood flow to the lower limbs.
This Phase 2a open-label study will evaluate the safety, tolerability, and dosing regimen of the heparin proteoglycan mimetic APAC in patients with PAOD with moderate claudication (Fontaine stage IIa and IIb) and in patients with CLTI (Fontaine stage III and IV) undergoing endovascular revascularization.
The study consists of two parts (Part A and Part B), both with two subparts:
- in Part A1, a single dose will be administered intravenously (i.v.),
- in Part A2, weekly doses will be administered i.v. for 4 weeks,
- in Part B1, a single dose will be administered intra-arterially (i.a) periprocedurally, and
- in Part B2, the first dose will be administered i.a. periprocedurally, followed by weekly i.v. dosing for 4 weeks.
Part A will evaluate APAC in the PAOD/CLTI patient population. The primary objective is to evaluate safety and tolerability of i.v. APAC for single infusion (Part A1) and weekly dosing (Part A2). Secondary objectives include evaluation of the effects of APAC on the clinical status of PAOD, and assessment of pharmacokinetic (PK), pharmacodynamic (PD) and other blood coagulation parameters. In Part A1, patients are randomized (2:1) to APAC and control groups. In Part A2, patients are randomized (2:2:1) to two APAC dose levels and control. In Part A, safety and recommended dose(s) of APAC for Part B are studied. A Safety Review Committee (SRC) will evaluate the Part A1 and Part A2 data after all patients in a group have completed the Day 8 or Day 29 visit, respectively, and decide the use of reserve doses, and recommend the dose(s) for the Part B.
Part B will evaluate APAC in CTLI patients undergoing endovascular revascularization. As primary objective, safety of the selected dose(s) and dosing frequency of periprocedural i.a. and weekly i.v. APAC administration will be evaluated. Secondary objectives aim to establish a dosing regimen (single vs. multiple dosing) and preliminary efficacy. Moreover, PK, PD and other blood coagulation parameters, as well as the effects of APAC on MALE and MACE-free survival and quality of life will be assessed as secondary objectives.
For both subparts (B1 and B2), patients will be randomized in 2:1 ratio to APAC and control groups. Part B1 with periprocedural dosing can start after the favorable SRC statement from Part A1. All other study parts (Part A1 [Day 8], Part A2 [Day 29], and Part B1 [Day 29]) need to be finalized before the start of Part B2.
For all study patients, the duration of screening period is maximum 28 days. Safety and clinical measures will be collected until the end of the follow-up period (Part A1: Day 29, and Parts A2, B1, B2: Day 90). To assess the effects of APAC on clinical outcome and quality of life, study participants will be followed up for 90 days in Part A1 and 180 days in Part A2, Part B1, and Part B2 after the first dose of APAC. The study ends when the patient has completed the Day 90 (Part A1) and Day 180 (Part A2, B1, and B2) telephone survey to assess quality of life.
- Being tested
- APAC - dose level 0.50 mg/kg,, Unfractionated heparin (UFH), APAC dose level 1: 0.25 mg/kg,, Vehicle (sterile saline, NaCL 0.9%), APAC dose level 2: 0.50 mg/kg,
- Medical subject headings
- Peripheral Arterial Occlusive Disease 1, Chronic Limb-Threatening Ischemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
APAC - dose level 0.50 mg/kg,Drug
single i.v. dosing
Unfractionated heparin (UFH)Other
administered as standard of care
APAC dose level 1: 0.25 mg/kg,Drug
weekly i.v. dosing for 4 consecutive weeks
Vehicle (sterile saline, NaCL 0.9%)Other
weekly i.v. dosing for 4 consecutive weeks
APAC dose level 2: 0.50 mg/kg,Drug
weekly i.v. dosing for 4 consecutive weeks
APAC (single periprocedural dose)Drug
Dose is selected based on Part A data, periprocedural dosing.
APACDrug
Dose is selected based on Part A and Part B, periprocedural dosing plus dosing for 4 consecutive weeks.
| Study group | Role | What they receive |
|---|---|---|
| Part A1 (no endovascular procedure) - APAC | Experimental | Not described Receives: Drug: APAC - dose level 0.50 mg/kg, |
| Part A1 (no endovascular procedure) - control | Active comparator | Not described Receives: Other: Unfractionated heparin (UFH) |
| Part A2 (no endovascular procedure) - APAC dose level 1 | Experimental | Not described Receives: Drug: APAC dose level 1: 0.25 mg/kg, |
| Part A2 (no endovascular procedure) - APAC dose level 2 | Experimental | Not described Receives: Drug: APAC dose level 2: 0.50 mg/kg, |
| Part A2 (no endovascular procedure) - vehicle | Other | Not described Receives: Other: Vehicle (sterile saline, NaCL 0.9%) |
| Part B1 (endovascular procedure) - APAC | Experimental | Not described Receives: Drug: APAC (single periprocedural dose) |
| Part B1 (endovascular procedure) - control | Active comparator | Not described Receives: Other: Unfractionated heparin (UFH) |
| Part B2 (endovascular procedure) - APAC | Experimental | Not described Receives: Drug: APAC |
| Part B2 (endovascular procedure) - control | Active comparator | Not described Receives: Other: Unfractionated heparin (UFH) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary endpoint - Part A: Occurrence and severity of treatment-emergent adverse events (TEAEs)
Measured: From baseline to Day 29 (Part A1) and Day 90 (Part A2) after the first dose of APAC
Primary endpoint - Part B: Occurrence and severity of TEAEs
Measured: From baseline to Day 90 after the first dose of APAC
Secondary outcomes (31)
Secondary endpoint 1 - Part A: Fontaine classification
No unit of measure
Measured: Assessed at screening (Day -28 to Day -1), at Day 29, Day 60 (Part A2 only) and Day 90 (Part A2) after the first dose of APAC
Secondary endpoint 1 - Part A: Wound Ischemia foot Infection (WIfI) scoring
No unit of measure
Measured: Assessed at screening (Day -28 to Day -1), at Day 8, Day 15 (Part A2 only), Day 22 (Part A2 only), Day 29, Day 60 (Part A2 only) and Day 90 (Part A2) after the first dose of APAC
Secondary endpoint 1 - Part A: Toe-brachial blood pressure index (TBI) and ankle-brachial systolic blood pressure index (ABI)
No unit of measure
Measured: Assessed at screening (Day -28 to Day -1) at Day 29, Day 60 (Part A2 only) and Day 90 (Part A2) after the first dose of APAC
Secondary endpoint 1 - Part A2: Maximal walking distance in a treadmill exercise test
Unit of measure: meters
Measured: Assessed at screening (Day -28 to Day -1), at Day 29, Day 60 and Day 90 after the first dose of APAC
Secondary endpoint 2 - Part A: Changes in PD and PK, and other blood coagulation biomarkers - clotting time, clot formation time and activated clotting time
Unit of measure: seconds
Measured: Assessed at baseline (Day 1), Day 2, Day 8, Day 15 (only Part A2), Day 22 (only Part A2) and Day 29
Secondary endpoint 2 - Part A: Changes in PD and PK, and other blood coagulation biomarkers - Maximum clot firmness
Unit of measure: millimeter
Measured: Assessed at baseline (Day 1), Day 2, Day 8, Day 15 (only Part A2), Day 22 (only Part A2) and Day 29
Secondary endpoint 2 - Part A: Changes in PD and PK and other coagulation parameters - Activated partial thromboplastin time
Unit of measure: seconds
Measured: Assessed at screening (Day -28 to -1), baseline (Day 1), Day 2, Day 8, Day 15 (only Part A2), Day 22 (only Part A2), Day 29, Day 60 (only Part A2) and Day 90 (only Part A2) after the first dose of APAC
Secondary endpoint 2 - Part A: Changes in PD and PK and other coagulation parameters - Anti-Factor IIa activity
Unit of measure: International Units per milliliter (IU/mL)
Measured: Assessed at baseline (Day 1), Day 2, Day 8, Day 15 (only Part A2) and Day 22 (only Part A2) after the first dose of APAC
Secondary endpoint 2 - Part A: Changes in PD and PK and other coagulation parameters - Anti-Factor Xa activity
Unit of measure: International Units per milliliter (IU/mL)
Measured: Assessed at screening (Day -28 to -1), baseline (Day 1), Day 22 (only Part A2), Day 29, Day 60 (only Part A2) and Day 90 (only Part A2) after the first dose of APAC
Secondary endpoint 2 - Part A: Changes in PD and PK and other coagulation parameters - Fibrinogen
Unit of measure: gram per milliliter (g/mL)
Measured: Assessed at screening (Day -28 to -1), baseline (Day 1), Day 22 (only Part A2), Day 29, Day 60 (only Part A2) and Day 90 (only Part A2) after the first dose of APAC
Secondary endpoint 2 - Part A: Changes in PD and PK and other coagulation parameters - von Willebrand factor antigen (VWF:Ag) and von Willebrand factor activity with gain-of function mutant Glycoprotein Ib fragment [VWF:GPIbM])
Unit of measure: percent
Measured: Assessed at screening (Day -28 to -1), baseline (Day 1), Day 22 (only Part A2), Day 29, Day 60 (only Part A2) and Day 90 (only Part A2) after the first dose of APAC
Secondary endpoint 3 - Part A: Major adverse limb event (MALE)- and major adverse cardiovascular event (MACE)-free survival
Unit of measure: percentage of patients
Measured: Assessed at screening (Day -28 to -1), at Day 29, Day 90 (Part A1) and Day 180 (Part A2) after the first dose of APAC
Secondary endpoint 3 - Part A: Quality of life questionnaire European Quality of life-5 Dimensions-3 Level (EQ-5D-5L)
No unit of measure. This questionnaire uses a scale from 0-100 where higher values mean a better outcome.
Measured: Assessed at screening (Day -28 to -1), at Day 29, D90 (Part A1) and D180 (Part A2) after the first dose of APAC
Secondary endpoint 3 - Part A: Ischemic pain
Assessed using the visual analog scale ranging from 0-100 where 0 = "No Pain" and 100 = "Worst Pain Imaginable"
Measured: From screening (Day -28 to -1), at Day 29, D90 (Part A1) and D180 (Part A2) after the first dose of APAC
Secondary endpoint 3 - Part A: Number of participants with ischemic ulcers or gangrene
No unit of measure. This will be assessed as per the clinicians judgement (Normal/Abnormal, Not clinically significant/Abnormal, Clinically significant).
Measured: From screening (Day -28 to -1), Day 29, D90 (Part A1) and D180 (Part A2) after the first dose of APAC
Secondary endpoint 3 - Part A: Physical performance questionnaire
No unit of measure.
This will be assessed by asking participants to report their ability to conduct the following activities: Walking around your home, Walking 1-2 blocks on level ground, Walking 1-2 blocks up a hill, Walking 3-4 blocks on level ground, Hurrying or jogging (as if to catch a bus), Vigorous work or exercise.
For each activity, participants will be asked to select one of the following answer options: Extremely limited, Quite a bit limited, Moderately limited, Slightly limited, Not at all limited, Limited for other reason or did not do the activity.
Measured: From screening (Day -28 to -1), at Day 29, D90 (Part A1) and D180 (Part A2) after the first dose of APAC
Secondary endpoint 1 - Part B: Fontaine classification
No unit of measure
Measured: Assessed at screening (Day -28 to -1), at Day 29, Day 36, Day 60 and Day 90 after the first dose of APAC
Secondary endpoint 1 - Part B: WIfI scoring
No unit of measure
Measured: Assessed at screening (Day -28 to -1), at Day 8 (only Part B2), Day 15 (only Part B2), Day 29, Day 36, Day 60 and Day 90 after the first dose of APAC
Secondary endpoint 1 - Part B: Outcome of recanalization (TBI and ABI) at rest
No unit of measure
Measured: Assessed at screening (Day -28 to -1), at Day 29, Day 36, Day 60 and Day 90 after the first dose of APAC
Secondary endpoint 2 - Part B: Changes in PD and PK, and other blood coagulation biomarkers - Clotting time, clot formation time and activated clotting time
Unit of measure: seconds
Measured: Assessed at baseline (Day 1), Day 2, Day 8, Day 15 (only Part B2), Day 22 (only Part B2), Day 29 and Day 36 (only Part B2)
Secondary endpoint 2 - Part B: Changes in PD and PK, and other blood coagulation biomarkers - Maximum clot firmness
Unit of measure: millimeter
Measured: Assessed at baseline (Day 1), Day 2, Day 8, Day 15 (only Part B2), Day 22 (only Part B2), Day 29 and Day 36 (only Part B2)
Secondary endpoint 2 - Part B: Changes in PD and PK and other coagulation parameters - Activated partial thromboplastin time (APTT)
Unit of measure: seconds
Measured: Assessed at screening (Day -28 to -1), baseline (Day 1), Day 2, Day 8, Day 15 (only Part B2), Day 22 (only Part B2), Day 29, Day 36 (only Part B2), Day 60 (only Part B2) and Day 90 (only Part B2) after the first dose of APAC
Secondary endpoint 2 - Part B: Changes in PD and PK and other coagulation parameters - Anti-Factor IIa activity
Unit of measure: International Units per milliliter (IU/mL)
Measured: Assessed at baseline (Day 1), Day 2, Day 8, Day 15 (only Part A2), Day 22 (only Part A2), and Day 29 after the first dose of APAC
Secondary endpoint 2 - Part B: Changes in PD and PK and other coagulation parameters - Anti-Factor Xa activity
Unit of measure: International Units per milliliter (IU/mL)
Measured: Assessed at screening (Day -28 to -1), baseline (Day 1), Day 29, Day 36 (only Part B2), Day 60 (only Part B2) and Day 90 (only Part B2) after the first dose of APAC
Secondary endpoint 2 - Part B: Changes in PD and PK and other coagulation parameters - Fibrinogen
Unit of measure: gram per milliliter (g/mL)
Measured: Assessed at screening (Day -28 to -1), baseline (Day 1), Day 29, Day 36 (only Part B2), Day 60 (only Part B2) and Day 90 (only Part B2) after the first dose of APAC
Secondary endpoint 2 - Part A: Changes in PD and PK and other coagulation parameters - von Willebrand factor antigen (VWF:Ag) and von Willebrand factor activity with gain-of function mutant Glycoprotein Ib fragment (VWF:GPIbM))
Unit of measure: percent
Measured: Assessed at screening (Day -28 to -1), baseline (Day 1), Day 29, Day 36 (Part B2), Day 60 (only Part B2) and Day 90 (only Part B2) after the first dose of APAC
Secondary endpoint 3 - Part B: MALE and MACE-free survival
Unit of measure: percentage of patients
Measured: Assessed at screening (Day -28 to Day -1), at Day 36, Day 90 and Day 180 after the first dose of APAC
Secondary endpoint 3 - Part B: Quality of life questionnaire European Quality of life-5 Dimensions-3 Level (EQ-5D-5L)
No unit of measure. This questionnaire uses a scale from 0-100 where higher values mean a better outcome.
Measured: Assessed at screening (Day -28 to -1), at Day 36, Day 90 and Day 180 after the first dose of APAC
Secondary endpoint 3 - Part B: Ischemic pain
Assessed using the visual analog scale ranging from 0-100 where 0 = "No Pain" and 100 = "Worst Pain Imaginable"
Measured: Assessed at screening (Day -28 to -1), at Day 36, Day 90 and Day 180 after the first dose of APAC
Secondary endpoint 3 - Part B: Number of participants with ischemic ulcers or gangrene
No unit of measure. This will be assessed as per the clinicians judgement (Normal/Abnormal, Not clinically significant/Abnormal, Clinically significant).
Measured: Assessed at screening (Day -28 to -1), at Day 36, Day 90 and Day 180 after the first dose of APAC
Secondary endpoint 3 - Part B: Physical performance questionnaire
No unit of measure.
This will be assessed by asking participants to report their ability to conduct the following activities: Walking around your home, Walking 1-2 blocks on level ground, Walking 1-2 blocks up a hill, Walking 3-4 blocks on level ground, Hurrying or jogging (as if to catch a bus), Vigorous work or exercise.
For each activity, participants will be asked to select one of the following answer options: Extremely limited, Quite a bit limited, Moderately limited, Slightly limited, Not at all limited, Limited for other reason or did not do the activity.
Measured: Assessed at screening (Day -28 to -1), at Day 36, Day 90 and Day 180 after the first dose of APAC
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jan 2026
- Study start29 Jan 2026
- Primary completion30 Jun 2027 (estimated)
- Study completion30 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Peripheral Arterial Occlusive DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Model description
- The study consists of two Parts - Part A and B, each divided into subparts 1 and 2. In Part A1, patients are randomized (2:1) to APAC and control groups. In Part A2, patients are randomized (2:2:1) to two APAC dose levels and control. In Part B (both subparts B1 and B2), patients will be randomized in 2:1 ratio to APAC and control groups.
- Masking
- None (open label)
- Enrolment
- 42 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Aplagon Oy
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Link Medical Research AB, Estimates OY
- Responsible party
- Sponsor
- Investigators
- Jarna Hannukainen, Study director, Aplagon Oy
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07352800
- Sponsor's protocol ID
- APLA-PAOD-CS02
- Other IDs
- 2025-522390-11-00, 2025
- Acronym
- HEALING
- Status last verified
- Apr 2026
- First submitted
- 21 Nov 2025
- Last updated
- 9 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2a Open-label Study to Assess the Safety, Tolerability, and Dosing Regimen of Antithrombotic Heparin Proteoglycan Mimetic APAC in Patients With Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia Undergoing Endovascular Revascularization
- ClinicalTrials.gov ID
- NCT07352800
- Acronym / sponsor ID
- HEALING / APLA-PAOD-CS02
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 42 participants (estimated)
- Lead sponsor
- Aplagon OyIndustry (pharma, biotech, devices)
- Collaborators
- Link Medical Research AB, Estimates OY
- Study start
- 29 Jan 2026 (actual)
- Primary completion
- 30 Jun 2027 (estimated)
- Study completion
- 30 Jun 2027 (estimated)
- First posted
- 20 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to learn if a new medicine (called antiplatelet and anticoagulant [APAC]) can help the body to prevent blood clots and whether APAC is safe and well tolerated in patients with blocked or narrowed arteries in their legs (peripheral arterial occlusive disease [PAOD]), and in patients with severely restricted poor blood flow to the legs that threatens limb health (chronic limb-threatening ischemia [CTLI]). The study also aims to find the best dose of the medicine. The study consists of two parts: Part A will include patients with PAOD and CTLI, Part B will only include patients with CTLI who are having a procedure to restore blood flow in their legs. Both parts will be subdivided into two subgroups (A1 and A2, B1 and B2) which will test different APAC doses and compare single dosing to weekly dosing for 4 weeks. APAC is injected into the blood. The possible treatment response will be compared either to a placebo (a look-alike substance that contains no drug), or to the current standard treatment. Patients will participate in the study for up to 90 or 180 days. During this time, patients will be regularly examined and asked to answer questions concerning their quality of life.
Detailed description
Peripheral arterial occlusive disease is a group of vascular disorders characterized by narrowing and occlusion of peripheral arteries, often resulting in gradual reduction of the blood supply to the limbs. The main pathogenic mechanism of PAOD stems from atherosclerosis, thrombo-inflammation and thrombosis (atherothrombosis). Patients with PAOD are at increased risk of major adverse limb events (MALE, defined as above ankle amputation of the index limb or major reintervention) and major adverse cardiovascular events (MACE). The most severe form of PAOD, CTLI, is characterized by severely decreased blood flow to the lower limbs.
This Phase 2a open-label study will evaluate the safety, tolerability, and dosing regimen of the heparin proteoglycan mimetic APAC in patients with PAOD with moderate claudication (Fontaine stage IIa and IIb) and in patients with CLTI (Fontaine stage III and IV) undergoing endovascular revascularization.
The study consists of two parts (Part A and Part B), both with two subparts:
- in Part A1, a single dose will be administered intravenously (i.v.),
- in Part A2, weekly doses will be administered i.v. for 4 weeks,
- in Part B1, a single dose will be administered intra-arterially (i.a) periprocedurally, and
- in Part B2, the first dose will be administered i.a. periprocedurally, followed by weekly i.v. dosing for 4 weeks.
Part A will evaluate APAC in the PAOD/CLTI patient population. The primary objective is to evaluate safety and tolerability of i.v. APAC for single infusion (Part A1) and weekly dosing (Part A2). Secondary objectives include evaluation of the effects of APAC on the clinical status of PAOD, and assessment of pharmacokinetic (PK), pharmacodynamic (PD) and other blood coagulation parameters. In Part A1, patients are randomized (2:1) to APAC and control groups. In Part A2, patients are randomized (2:2:1) to two APAC dose levels and control. In Part A, safety and recommended dose(s) of APAC for Part B are studied. A Safety Review Committee (SRC) will evaluate the Part A1 and Part A2 data after all patients in a group have completed the Day 8 or Day 29 visit, respectively, and decide the use of reserve doses, and recommend the dose(s) for the Part B.
Part B will evaluate APAC in CTLI patients undergoing endovascular revascularization. As primary objective, safety of the selected dose(s) and dosing frequency of periprocedural i.a. and weekly i.v. APAC administration will be evaluated. Secondary objectives aim to establish a dosing regimen (single vs. multiple dosing) and preliminary efficacy. Moreover, PK, PD and other blood coagulation parameters, as well as the effects of APAC on MALE and MACE-free survival and quality of life will be assessed as secondary objectives.
For both subparts (B1 and B2), patients will be randomized in 2:1 ratio to APAC and control groups. Part B1 with periprocedural dosing can start after the favorable SRC statement from Part A1. All other study parts (Part A1 [Day 8], Part A2 [Day 29], and Part B1 [Day 29]) need to be finalized before the start of Part B2.
For all study patients, the duration of screening period is maximum 28 days. Safety and clinical measures will be collected until the end of the follow-up period (Part A1: Day 29, and Parts A2, B1, B2: Day 90). To assess the effects of APAC on clinical outcome and quality of life, study participants will be followed up for 90 days in Part A1 and 180 days in Part A2, Part B1, and Part B2 after the first dose of APAC. The study ends when the patient has completed the Day 90 (Part A1) and Day 180 (Part A2, B1, and B2) telephone survey to assess quality of life.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 9
- Model description
- The study consists of two Parts - Part A and B, each divided into subparts 1 and 2. In Part A1, patients are randomized (2:1) to APAC and control groups. In Part A2, patients are randomized (2:2:1) to two APAC dose levels and control. In Part B (both subparts B1 and B2), patients will be randomized in 2:1 ratio to APAC and control groups.
| Arm | Type | Receives |
|---|---|---|
| Part A1 (no endovascular procedure) - APAC | Experimental | Drug: APAC - dose level 0.50 mg/kg, |
| Part A1 (no endovascular procedure) - control | Active comparator | Other: Unfractionated heparin (UFH) |
| Part A2 (no endovascular procedure) - APAC dose level 1 | Experimental | Drug: APAC dose level 1: 0.25 mg/kg, |
| Part A2 (no endovascular procedure) - APAC dose level 2 | Experimental | Drug: APAC dose level 2: 0.50 mg/kg, |
| Part A2 (no endovascular procedure) - vehicle | Other | Other: Vehicle (sterile saline, NaCL 0.9%) |
| Part B1 (endovascular procedure) - APAC | Experimental | Drug: APAC (single periprocedural dose) |
| Part B1 (endovascular procedure) - control | Active comparator | Other: Unfractionated heparin (UFH) |
| Part B2 (endovascular procedure) - APAC | Experimental | Drug: APAC |
| Part B2 (endovascular procedure) - control | Active comparator | Other: Unfractionated heparin (UFH) |
Who may qualify
- Ages
- Up to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (17 listed)
- Males aged 45-85 years and postmenopausal females (i.e., no menstrual periods for 12 months without an alternative medical cause) up to 85 years.
- Diagnosed with a. PAOD classification Fontaine stage III or IV , b. the total length of the treatment-targeted arterial segment ≥ 5 cm below the knee lesion(s) based on contrast-enhanced computed tomography angiography (CTA)/magnetic resonance angiography (MRA)/digital subtraction angiography (DSA) (Part B1 and B2), c. superficial forefoot wounds without overt infection and bone invasion (WIfI 0-1 and 2 limited to digits and WIfI infection 0-1) allowed, d. undergoing endovascular intervention. (In Part A1, if prescheduled endovascular intervention would take place before the Day 8 study visit, patient is not to be enrolled.)
- CTA/MRA/DSA with contrast agent performed within 3 months prior to study enrolment as part of diagnostics of PAOD, with results available in the patient's medical records.
- Patients should be treated with antithrombotic medication either acetylsalicylic acid (up to 100 mg once a day [QD]) or clopidogrel (up to 75 mg QD) for at least the preceding five days before the first APAC administration.
- Adequate lipid lowering therapy, as evaluated by the investigator.
Key exclusion criteria (32 listed)
- Any ischemic lesions of the heel and midfoot and lesions (wounds or gangrene) invading bones, joints, or tendons at metatarsophalangeal joints or more proximal sites.
- Acute limb-threatening ischemia (e.g., thromboembolic disease).
- Medical history of, or an existing aneurysm.
- Endovascular revascularization intervention is done from the contralateral side using cross-over access (Part B1 and B2).
- Medical history of, or condition known to be associated with impaired hemostasis, i.e., increased intracranial bleeding risk e.g., previous history of intracranial hemorrhage, subarachnoidal bleeding, hemorrhagic stroke, thrombotic or thromboembolic stroke, gastrointestinal bleeding within 6 months of enrolment, or retroperitoneal bleeding any time, or any inherited or acquired bleeding disorder, i.e., von Willebrand disease or hemophilia or other relevant diagnosis causing impaired hemostasis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| APAC - dose level 0.50 mg/kg,single i.v. dosing | Drug | Part A1 (no endovascular procedure) - APAC |
| Unfractionated heparin (UFH)administered as standard of care | Other | Part A1 (no endovascular procedure) - control, Part B1 (endovascular procedure) - control, Part B2 (endovascular procedure) - control |
| APAC dose level 1: 0.25 mg/kg,weekly i.v. dosing for 4 consecutive weeks | Drug | Part A2 (no endovascular procedure) - APAC dose level 1 |
| Vehicle (sterile saline, NaCL 0.9%)weekly i.v. dosing for 4 consecutive weeks | Other | Part A2 (no endovascular procedure) - vehicle |
| APAC dose level 2: 0.50 mg/kg,weekly i.v. dosing for 4 consecutive weeks | Drug | Part A2 (no endovascular procedure) - APAC dose level 2 |
| APAC (single periprocedural dose)Dose is selected based on Part A data, periprocedural dosing. | Drug | Part B1 (endovascular procedure) - APAC |
| APACDose is selected based on Part A and Part B, periprocedural dosing plus dosing for 4 consecutive weeks. | Drug | Part B2 (endovascular procedure) - APAC |
Primary outcome
Primary endpoint - Part A: Occurrence and severity of treatment-emergent adverse events (TEAEs)
Time frame: From baseline to Day 29 (Part A1) and Day 90 (Part A2) after the first dose of APAC
Primary endpoint - Part B: Occurrence and severity of TEAEs
Time frame: From baseline to Day 90 after the first dose of APAC
31 secondary outcomes
Secondary endpoint 1 - Part A: Fontaine classification
Time frame: Assessed at screening (Day -28 to Day -1), at Day 29, Day 60 (Part A2 only) and Day 90 (Part A2) after the first dose of APAC
Secondary endpoint 1 - Part A: Wound Ischemia foot Infection (WIfI) scoring
Time frame: Assessed at screening (Day -28 to Day -1), at Day 8, Day 15 (Part A2 only), Day 22 (Part A2 only), Day 29, Day 60 (Part A2 only) and Day 90 (Part A2) after the first dose of APAC
Secondary endpoint 1 - Part A: Toe-brachial blood pressure index (TBI) and ankle-brachial systolic blood pressure index (ABI)
Time frame: Assessed at screening (Day -28 to Day -1) at Day 29, Day 60 (Part A2 only) and Day 90 (Part A2) after the first dose of APAC
Secondary endpoint 1 - Part A2: Maximal walking distance in a treadmill exercise test
Time frame: Assessed at screening (Day -28 to Day -1), at Day 29, Day 60 and Day 90 after the first dose of APAC
Secondary endpoint 2 - Part A: Changes in PD and PK, and other blood coagulation biomarkers - clotting time, clot formation time and activated clotting time
Time frame: Assessed at baseline (Day 1), Day 2, Day 8, Day 15 (only Part A2), Day 22 (only Part A2) and Day 29
Secondary endpoint 2 - Part A: Changes in PD and PK, and other blood coagulation biomarkers - Maximum clot firmness
Time frame: Assessed at baseline (Day 1), Day 2, Day 8, Day 15 (only Part A2), Day 22 (only Part A2) and Day 29
Secondary endpoint 2 - Part A: Changes in PD and PK and other coagulation parameters - Activated partial thromboplastin time
Time frame: Assessed at screening (Day -28 to -1), baseline (Day 1), Day 2, Day 8, Day 15 (only Part A2), Day 22 (only Part A2), Day 29, Day 60 (only Part A2) and Day 90 (only Part A2) after the first dose of APAC
Secondary endpoint 2 - Part A: Changes in PD and PK and other coagulation parameters - Anti-Factor IIa activity
Time frame: Assessed at baseline (Day 1), Day 2, Day 8, Day 15 (only Part A2) and Day 22 (only Part A2) after the first dose of APAC
Secondary endpoint 2 - Part A: Changes in PD and PK and other coagulation parameters - Anti-Factor Xa activity
Time frame: Assessed at screening (Day -28 to -1), baseline (Day 1), Day 22 (only Part A2), Day 29, Day 60 (only Part A2) and Day 90 (only Part A2) after the first dose of APAC
Secondary endpoint 2 - Part A: Changes in PD and PK and other coagulation parameters - Fibrinogen
Time frame: Assessed at screening (Day -28 to -1), baseline (Day 1), Day 22 (only Part A2), Day 29, Day 60 (only Part A2) and Day 90 (only Part A2) after the first dose of APAC
Secondary endpoint 2 - Part A: Changes in PD and PK and other coagulation parameters - von Willebrand factor antigen (VWF:Ag) and von Willebrand factor activity with gain-of function mutant Glycoprotein Ib fragment [VWF:GPIbM])
Time frame: Assessed at screening (Day -28 to -1), baseline (Day 1), Day 22 (only Part A2), Day 29, Day 60 (only Part A2) and Day 90 (only Part A2) after the first dose of APAC
Secondary endpoint 3 - Part A: Major adverse limb event (MALE)- and major adverse cardiovascular event (MACE)-free survival
Time frame: Assessed at screening (Day -28 to -1), at Day 29, Day 90 (Part A1) and Day 180 (Part A2) after the first dose of APAC
Secondary endpoint 3 - Part A: Quality of life questionnaire European Quality of life-5 Dimensions-3 Level (EQ-5D-5L)
Time frame: Assessed at screening (Day -28 to -1), at Day 29, D90 (Part A1) and D180 (Part A2) after the first dose of APAC
Secondary endpoint 3 - Part A: Ischemic pain
Time frame: From screening (Day -28 to -1), at Day 29, D90 (Part A1) and D180 (Part A2) after the first dose of APAC
Secondary endpoint 3 - Part A: Number of participants with ischemic ulcers or gangrene
Time frame: From screening (Day -28 to -1), Day 29, D90 (Part A1) and D180 (Part A2) after the first dose of APAC
Secondary endpoint 3 - Part A: Physical performance questionnaire
Time frame: From screening (Day -28 to -1), at Day 29, D90 (Part A1) and D180 (Part A2) after the first dose of APAC
Secondary endpoint 1 - Part B: Fontaine classification
Time frame: Assessed at screening (Day -28 to -1), at Day 29, Day 36, Day 60 and Day 90 after the first dose of APAC
Secondary endpoint 1 - Part B: WIfI scoring
Time frame: Assessed at screening (Day -28 to -1), at Day 8 (only Part B2), Day 15 (only Part B2), Day 29, Day 36, Day 60 and Day 90 after the first dose of APAC
Secondary endpoint 1 - Part B: Outcome of recanalization (TBI and ABI) at rest
Time frame: Assessed at screening (Day -28 to -1), at Day 29, Day 36, Day 60 and Day 90 after the first dose of APAC
Secondary endpoint 2 - Part B: Changes in PD and PK, and other blood coagulation biomarkers - Clotting time, clot formation time and activated clotting time
Time frame: Assessed at baseline (Day 1), Day 2, Day 8, Day 15 (only Part B2), Day 22 (only Part B2), Day 29 and Day 36 (only Part B2)
Secondary endpoint 2 - Part B: Changes in PD and PK, and other blood coagulation biomarkers - Maximum clot firmness
Time frame: Assessed at baseline (Day 1), Day 2, Day 8, Day 15 (only Part B2), Day 22 (only Part B2), Day 29 and Day 36 (only Part B2)
Secondary endpoint 2 - Part B: Changes in PD and PK and other coagulation parameters - Activated partial thromboplastin time (APTT)
Time frame: Assessed at screening (Day -28 to -1), baseline (Day 1), Day 2, Day 8, Day 15 (only Part B2), Day 22 (only Part B2), Day 29, Day 36 (only Part B2), Day 60 (only Part B2) and Day 90 (only Part B2) after the first dose of APAC
Secondary endpoint 2 - Part B: Changes in PD and PK and other coagulation parameters - Anti-Factor IIa activity
Time frame: Assessed at baseline (Day 1), Day 2, Day 8, Day 15 (only Part A2), Day 22 (only Part A2), and Day 29 after the first dose of APAC
Secondary endpoint 2 - Part B: Changes in PD and PK and other coagulation parameters - Anti-Factor Xa activity
Time frame: Assessed at screening (Day -28 to -1), baseline (Day 1), Day 29, Day 36 (only Part B2), Day 60 (only Part B2) and Day 90 (only Part B2) after the first dose of APAC
Secondary endpoint 2 - Part B: Changes in PD and PK and other coagulation parameters - Fibrinogen
Time frame: Assessed at screening (Day -28 to -1), baseline (Day 1), Day 29, Day 36 (only Part B2), Day 60 (only Part B2) and Day 90 (only Part B2) after the first dose of APAC
Secondary endpoint 2 - Part A: Changes in PD and PK and other coagulation parameters - von Willebrand factor antigen (VWF:Ag) and von Willebrand factor activity with gain-of function mutant Glycoprotein Ib fragment (VWF:GPIbM))
Time frame: Assessed at screening (Day -28 to -1), baseline (Day 1), Day 29, Day 36 (Part B2), Day 60 (only Part B2) and Day 90 (only Part B2) after the first dose of APAC
Secondary endpoint 3 - Part B: MALE and MACE-free survival
Time frame: Assessed at screening (Day -28 to Day -1), at Day 36, Day 90 and Day 180 after the first dose of APAC
Secondary endpoint 3 - Part B: Quality of life questionnaire European Quality of life-5 Dimensions-3 Level (EQ-5D-5L)
Time frame: Assessed at screening (Day -28 to -1), at Day 36, Day 90 and Day 180 after the first dose of APAC
Secondary endpoint 3 - Part B: Ischemic pain
Time frame: Assessed at screening (Day -28 to -1), at Day 36, Day 90 and Day 180 after the first dose of APAC
Secondary endpoint 3 - Part B: Number of participants with ischemic ulcers or gangrene
Time frame: Assessed at screening (Day -28 to -1), at Day 36, Day 90 and Day 180 after the first dose of APAC
Secondary endpoint 3 - Part B: Physical performance questionnaire
Time frame: Assessed at screening (Day -28 to -1), at Day 36, Day 90 and Day 180 after the first dose of APAC
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Peripheral Arterial Occlusive Disease
Active, not recruiting
SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA Study
Peripheral Artery Disease
RecruitingPhase 3
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
Peripheral Artery Disease (PAD)
Recruiting
The THOR IDE Study
Peripheral Artery Disease, Peripheral Artery Stenosis
Not yet recruiting
Daily Stretching to Improve Walking in Older Patients With Peripheral Artery Disease: The STRETCH PAD Study
Peripheral Artery Disease (PAD), Intermittent Claudication
Enrolling by invitationEarly Phase 1
Truway Diagnostic Tools in Primary Care
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jarna Hannukainen study director
Aplagon Oy
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing APAC - dose level 0.50 mg/kg,, Unfractionated heparin (UFH) and APAC dose level 1: 0.25 mg/kg, in people with Peripheral Arterial Occlusive Disease and Chronic Limb-Threatening Ischemia, run by Aplagon Oy at 3 sites in Finland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 17 inclusion and 32 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Finland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jarna Hannukainen (+358 400 633 061, jarna.hannukainen@aplagon.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary endpoint - Part A: Occurrence and severity of treatment-emergent adverse events (TEAEs) (time frame: From baseline to Day 29 (Part A1) and Day 90 (Part A2) after the first dose of APAC). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Apr 2026.